Plasma AR and abiraterone-resistant prostate cancer

Science Translational Medicine

Volumn 7, Issue 312, 2015, Pages

  Romanel, Alessandro ^a   Tandefelt, Delila Gasi ^b   Conteduca, Vincenza ^b,c   Jayaram, Anuradha ^b,d   Casiraghi, Nicola ^a   Wetterskog, Daniel ^b   Salvi, Samanta ^c   Amadori, Dino ^c   Zafeiriou, Zafeiris ^b,d   Rescigno, Pasquale ^b,d   Bianchini, Diletta ^b,d   Gurioli, Giorgia ^c   Casadio, Valentina ^c   Carreira, Suzanne ^b   Goodall, Jane ^b   Wingate, Anna ^b,d   Ferraldeschi, Roberta ^b,d,g   Tunariu, Nina ^b,d   Flohr, Penny ^b   De Giorgi, Ugo ^c   De Bono, Johann S ^b,d   Demichelis, Francesca ^a,e,f   Attard, Gerhardt ^b,d   more..

^a UNIVERSITY OF TRENTO   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Weill Cornell Medicine   (United States)

^g ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; DNA; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; AR PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DOSAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BLOOD; COPY NUMBER VARIATION; DRUG RESISTANCE; GENETICS; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENES; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; YOUNG ADULT;

EID: 84947245381     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac9511     Document Type: Article

References (29)

1. J. S. de Bono, C. J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K. N. Chi, R. J. Jones, O. B. Goodman Jr., F. Saad, J. N. Staffurth, P. Mainwaring, S. Harland, T. W. Flaig, T. E. Hutson, T. Cheng, H. Patterson, J. D. Hainsworth, C. J. Ryan, C. N. Sternberg, S. L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C. M. Haqq, H. I. Scher; COU-AA-301 Investigators, Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. H. I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C. N. Sternberg, K. Miller, R. de Wit, P. Mulders, K. N. Chi, N. D. Shore, A. J. Armstrong, T. W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. D. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. S. de Bono; AFFIRM Investigators, Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
3. D. Robinson, E. M. Van Allen, Y.-M. Wu, N. Schultz, R. J. Lonigro, J.-M. Mosquera, B. Montgomery, M.-E. Taplin, C. C. Pritchard, G. Attard, H. Beltran, W. Abida, R. K. Bradley, J. Vinson, X. Cao, P. Vats, L. P. Kunju, M. Hussain, F. Y. Feng, S. A. Tomlins, K. A. Cooney, D. C. Smith, C. Brennan, J. Siddiqui, R. Mehra, Y. Chen, D. E. Rathkopf, M. J. Morris, S. B. Solomon, J. C. Durack, V. E. Reuter, A. Gopalan, J. Gao, M. Loda, R. T. Lis, M. Bowden, S. P. Balk, G. Gaviola, C. Sougnez, M. Gupta, E. Y. Yu, E. A. Mostaghel, H. H. Cheng, H. Mulcahy, L. D. True, S. R. Plymate, H. Dvinge, R. Ferraldeschi, P. Flohr, S. Miranda, Z. Zafeiriou, N. Tunariu, J. Mateo, R. Perez-Lopez, F. Demichelis, B. D. Robinson, M. Schiffman, D. M. Nanus, S. T. Tagawa, A. Sigaras, K. W. Eng, O. Elemento, A. Sboner, E. I. Heath, H. I. Scher, K. J. Pienta, P. Kantoff, J. S. de Bono, M. A. Rubin, P. S. Nelson, L. A. Garraway, C. L. Sawyers, A. M. Chinnaiyan, Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
4. H. Beltran, K. Eng, J. M. Mosquera, A. Sigaras, A. Romanel, H. Rennert, M. Kossai, C. Pauli, B. Faltas, J. Fontugne, K. Park, J. Banfelder, D. Prandi, N. Madhukar, T. Zhang, J. Padilla, N. Greco, T. J. McNary, E. Herrscher, D. Wilkes, T. Y. MacDonald, H. Xue, V. Vacic, A.-K. Emde, D. Oschwald, A. Y. Tan, Z. Chen, C. Collins, M. E. Gleave, Y. Wang, D. Chakravarty, M. Schiffman, R. Kim, F. Campagne, B. D. Robinson, D. M. Nanus, S. T. Tagawa, J. Z. Xiang, A. Smogorzewska, F. Demichelis, D. S. Rickman, A. Sboner, O. Elemento, M. A. Rubin, Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1, 466-474 (2015).
5. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med. 2, e73 (2005).
6. G. Gundem, P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. Tubio, E. Papaemmanuil, D. S. Brewer, H. M. Kallio, G. Högnäs, M. Annala, K. Kivinummi, V. Goody, C. Latimer, S. O'Meara, K. J. Dawson, W. Isaacs, M. R. Emmert-Buck, M. Nykter, C. Foster, Z. Kote-Jarai, D. Easton, H. C. Whitaker; ICGC Prostate UK Group, D. E. Neal, C. S. Cooper, R. A. Eeles, T. Visakorpi, P. J. Campbell, U. McDermott, D. C. Wedge, G. S. Bova, The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015).
7. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, L. M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
8. S.-J. Dawson, D. W. Y. Tsui, M. Murtaza, H. Biggs, O. M. Rueda, S.-F. Chin, M. J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas, N. Rosenfeld, Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
9. G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena, G. Crisafulli, A. Ponzetti, C. Cremolini, A. Amatu, C. Lauricella, S. Lamba, S. Hobor, A. Avallone, E. Valtorta, G. Rospo, E. Medico, V. Motta, C. Antoniotti, F. Tatangelo, B. Bellosillo, S. Veronese, A. Budillon, C. Montagut, P. Racca, S. Marsoni, A. Falcone, R. B. Corcoran, F. Di Nicolantonio, F. Loupakis, S. Siena, A. Sartore-Bianchi, A. Bardelli, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
10. S. Carreira, A. Romanel, J. Goodall, E. Grist, R. Ferraldeschi, S. Miranda, D. Prandi, D. Lorente, J.-S. Frenel, C. Pezaro, A. Omlin, D. N. Rodrigues, P. Flohr, N. Tunariu, J. S. de Bono, F. Demichelis, G. Attard, Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
11. E. Heitzer, P. Ulz, J. Belic, S. Gutschi, F. Quehenberger, K. Fischereder, T. Benezeder, M. Auer, C. Pischler, S. Mannweiler, M. Pichler, F. Eisner, M. Haeusler, S. Riethdorf, K. Pantel, H. Samonigg, G. Hoefler, H. Augustin, J. B. Geigl, M. R. Speicher, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5, 30 (2013).
12. M. Murtaza, S.-J. Dawson, D. W. Y. Tsui, D. Gale, T. Forshew, A. M. Piskorz, C. Parkinson, S.-F. Chin, Z. Kingsbury, A. S. C. Wong, F. Marass, S. Humphray, J. Hadfield, D. Bentley, T. M. Chin, J. D. Brenton, C. Caldas, N. Rosenfeld, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
13. C. Palmberg, P. Koivisto, L. Kakkola, T. L. J. Tammela, O. P. Kallioniemi, T. Visakorpi, Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 164, 1992-1995 (2000).
14. M.-E. Taplin, G. J. Bubley, T. D. Shuster, M. E. Frantz, A. E. Spooner, G. K. Ogata, H. N. Keer, S. P. Balk, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
15. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinänen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, O.-P. Kallioniemi, In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406 (1995).
16. D. Prandi, S. C. Baca, A. Romanel, C. E. Barbieri, J.-M. Mosquera, J. Fontugne, H. Beltran, A. Sboner, L. A. Garraway, M. A. Rubin, F. Demichelis, Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 15, 439 (2014).
17. J. C. Fay, C.-I. Wu, Sequence divergence, functional constraint, and selection in protein evolution. Annu. Rev. Genomics Hum. Genet. 4, 213-235 (2003).
18. L. D. Hurst, The Ka/Ks ratio: Diagnosing the form of sequence evolution. Trends Genet. 18, 486-487 (2002).
19. E. J. Chen, A. G. Sowalsky, S. Gao, C. Cai, O. Voznesensky, R. Schaefer, M. Loda, L. D. True, H. Ye, P. Troncoso, R. L. Lis, P. W. Kantoff, R. B. Montgomery, P. S. Nelson, G. J. Bubley, S. P. Balk, M.-E. Taplin, Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin. Cancer Res. 21, 1273-1280 (2015).
20. S. Salvi, V. Casadio, V. Conteduca, S. L. Burgio, C. Menna, E. Bianchi, L. Rossi, E. Carretta, C. Masini, D. Amadori, D. Calistri, G. Attard, U. De Giorgi, Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br. J. Cancer 112, 1717-1724 (2015).
21. A. A. Azad, S. V. Volik, A. W. Wyatt, A. Haegert, S. Le Bihan, R. H. Bell, S. A. Anderson, B. McConeghy, R. Shukin, J. Bazov, J. Youngren, P. Paris, G. Thomas, E. J. Small, Y. Wang, M. E. Gleave, C. C. Collins, K. N. Chi, Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315-2324 (2015).
22. E. S. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa, J. C. Roeser, Y. Chen, T. A. Mohammad, Y. Chen, H. L. Fedor, T. L. Lotan, Q. Zheng, A. M. De Marzo, J. T. Isaacs, W. B. Isaacs, R. Nadal, C. J. Paller, S. R. Denmeade, M. A. Carducci, M. A. Eisenberger, J. Luo, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
23. J. Steinestel, M. Luedeke, A. Arndt, T. J. Schnoeller, J. K. Lennerz, C. Wurm, C. Maier, M. V. Cronauer, K. Steinestel, A. J. Schrader, Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 10.18632/oncotarget.3925 (2015).
24. M. J. Linja, K. J. Savinainen, O. R. Saramäki, T. L. J. Tammela, R. L. Vessella, T. Visakorpi, Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555 (2001).
25. C. D. Chen, D. S. Welsbie, C. Tran, S. H. Baek, R. Chen, R. Vessella, M. G. Rosenfeld, C. L. Sawyers, Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
26. K. K. Waltering, M. A. Helenius, B. Sahu, V. Manni, M. J. Linja, O. A. Jänne, T. Visakorpi, Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69, 8141-8149 (2009).
27. H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W. K. Kelly, W. D. Figg, E. J. Small, T. M. Beer, G. Wilding, A. Martin, M. Hussain, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
28. C. J. Ryan, M. R. Smith, J. S. de Bono, A. Molina, C. J. Logothetis, P. de Souza, K. Fizazi, P. Mainwaring, J. M. Piulats, S. Ng, J. Carles, P. F. A. Mulders, E. Basch, E. J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S. D. Mukherjee, H. Suttmann, W. R. Gerritsen, T. W. Flaig, D. J. George, E. Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C. S. Higano, M.-E. Taplin, Y. Park, T. Kheoh, T. Griffin, H. I. Scher, D. E. Rathkopf; COU-AA-302 Investigators, Abiraterone in meta-static prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
29. A. Romanel, S. Lago, D. Prandi, A. Sboner, F. Demichelis, ASEQ: Fast allele-specific studies from next-generation sequencing data. BMC Med. Genomics 8, 9 (2015).